Advertisement

An unmet medical need vs. regulatory recommendations: how should we treat patients with hyperaldosteronism and advanced chronic kidney disease when surgery is not feasible?

  • Ivana MikačićEmail author
Letter to the Editor
  • 20 Downloads

A 40-year-old man presented with resistant arterial hypertension (HTA): his mean blood pressure was 155/91 mm Hg despite treatment with five classes of antihypertensives. He suffered from chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) 24 mL/min due to a long-standing HTA with biopsy-proven nephroangiosclerosis (Online Resource - SM1). His serum aldosterone was 4 times above the upper limit of normal and was not suppressed in the saline infusion test. Multi-slice computed tomography and magnetic resonance imaging indicated normal adrenal glands. Patient did not consider surgery as an option, and it was clear that he would have benefited from aldosterone-antagonizing therapy regarding both hypertension and preservation of the renal function by antagonism of the effects of aldosterone on renal sclerosis [1].

Two aldosterone antagonists are marketed throughout Europe: spironolactone and eplerenone. Canrenone, a spironolactone metabolite, is marketed as an...

Keywords

Hyperaldosteronism Chronic kidney disease Spironolactone Eplerenone 

Notes

Compliance with ethical standards

Conflict of interest

The author declares that she has no conflict of interest.

Supplementary material

228_2019_2774_MOESM1_ESM.docx (19 kb)
ESM 1 (DOCX 19.3 kb)

References

  1. 1.
    Capelli I, Gasperoni L, Ruggeri M, Donati G, Baraldi O, Sorrenti G, Caletti MT, Aiello V, Cianciolo G, la Manna G (2019) New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J Nephrol:1–12.  https://doi.org/10.1007/s40620-019-00600-7
  2. 2.
    Kolkhof P, Barfacker L (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. The Journal of endocrinology 234 (1):T125–T140CrossRefGoogle Scholar
  3. 3.
    Danjuma MI, Mukherjee I, Makaronidis J, Osula S (2014) Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 16(2):414.  https://doi.org/10.1007/s11906-013-0414-8 CrossRefPubMedGoogle Scholar
  4. 4.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717.  https://doi.org/10.1056/NEJM199909023411001 CrossRefPubMedGoogle Scholar
  5. 5.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239.  https://doi.org/10.1016/j.jacc.2013.05.019 CrossRefPubMedGoogle Scholar
  6. 6.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–ee61.  https://doi.org/10.1161/CIR.0000000000000509 CrossRefPubMedGoogle Scholar
  7. 7.
    Medicines.org.uk (2019) Spironolactone - summary of product characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/ingredient/36. Accessed 26 June 2019
  8. 8.
    Agencia Española de Medicamentos y Productos Sanitarios - AEMPS (2019) Espironolactona - Summary of Product Characteristics (SPC). https://cima.aemps.es/cima/publico/lista.html. Accessed 26 June 2019
  9. 9.
    Swedish Medical Products Agency (2019) Spironolakton -summary of product characteristics (SPC). https://lakemedelsverket.se/LMF/?q=Spironolakton&type=product. Accessed 27 June 2019
  10. 10.
    Agenzia Italiana del Farmaco - AIFA (2019) Luvion - Riassunto delle caratteristiche del prodotto. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000913_024273_RCP.pdf&retry=0&sys=m0b1l3. Assessed 26 Aug 2019
  11. 11.
    Medicines Evaluation Board (2019) Spironolacton - summary of product characteristics (SPC) https://www.geneesmiddeleninformatiebank.nl/nl/. Accessed 30 June 2019

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Unit for Clinical PharmacologyUniversity Hospital “Sveti Duh”ZagrebCroatia
  2. 2.Department of Internal Medicine, School of MedicineUniversity of ZagrebZagrebCroatia

Personalised recommendations